Our benign hematology specialists are committed to improving outcomes for cancer patients who suffer from benign blood disorders. Our bench-to-bedside approach means our patients are consistently offered newer, safer and more effective treatments as they are developed. Focusing on a broad range of blood diseases – coagulation disorders, thrombophilic disorders, sickle cell anemia and other benign hematologic disorders – these specialists work to:
- Optimize outcomes, both short- and long-term, for cancer patients who also have non-malignant blood disorders and patients who have non-malignant blood disorders.
- Research new methods of treating benign blood disorders, especially as they relate to the pathophysiology of blood and coagulation diseases
Learn about clinical trials, ongoing research and our team of benign hematology experts at the links below.
How to Refer